Award Data

The long term goal of the project is to use malaria parasite specific low-molecular-weight metabolites as biomarkers for development of sensitive, low-cost, simple, battery-operated field-deployable urine or saliva diagnostic biosensor for detection of malaria infection. Four malaria parasite-specific metabolites (3-Methylindole, Succinylacetone, S-Methyl-L-thiocitrulline, O-Arachidonoyl Glycidol ...

To improve the safety and efficacy of oral rotavirus vaccines, CDC scientists have developed a proprietary inactivated rotavirus vaccine (IRV) technology (new human strains and a novel method for rotavirus inactivation) and demonstrated the immunogenicity in mice [14] and protective efficacy in piglets [15] of this IRV by intramuscular (IM) administration. More recently, CDC scientists have demons ...

DESCRIPTION (provided by applicant): The purpose of this project is to develop and test Clear Cues (CC), a signage system for care communities that supports way finding in people with dementia. Way finding is a process through which people use informationin the environment to help them get to their desired destination. It's both the user experience of choosing a path and the design elements t ...

DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-accepted triple transgenic mouse model of AD (3xTg ...

DESCRIPTION (provided by applicant): Guild proposes to develop an antisense oligomer-based antifungal effective against the human pathogen Aspergillus fumigatus. With a 40%-60% mortality rate, invasive aspergillosis (IA) due to A. fumigatus now surpasses invasive candidiasis as the most frequent fungal cause of death, especially amongst immunocompromised patients. Successful therapy for IA with cu ...

DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is us ...

DESCRIPTION (provided by applicant): This is the Phase I application of a SBIR project that will be devoted to develop a new fecal DNA test for CRC screening, which will utilize a new tri-marker panel discovered in our preliminary study. CRC is the seconddeadliest cancer in USA. The good news is that early detection along with resection is associated with a five-year survival rate of nearly 100%. ...

Abstract A joint DOE-NCI workshop on ion beam therapy (January 2013, Bethesda, MD) has identified an ambitious set of technological developments needed to support a world-class treatment program for ion beam therapy. One important requirement is the ability to provide detectors that afford single-particle registration at high data rates with high degree of uniformity and minimal interference with ...

DESCRIPTION (provided by applicant): Biological RNAs undergo extensive post-transcriptional modifications. These modifications are important in promoting the accuracy and efficiency of gene expression in biological systems. To decipher the functions of RNA modifications, robust analytical tools and methods that enable scientists to monitor, manipulate, and transcriptome-wide mapping RNA modificat ...

DESCRIPTION (provided by applicant): Pre-mixed formulations of soluble prandial insulin analogs and NPH micro-crystalline suspensions provide a simplified and cost-effective basal-bolus regimen for patients with Type 2 diabetes mellitus (T2DM) not effectively controlled by basal insulin therapy alone. Such twice-daily products (in vials or pre-filled in pens) account for gt 2B in sales in the dev ...